TheraRadar
Data updated: May 26, 2026

CIPROFLOXACIN AND DEXAMETHASONE (ciprofloxacin)

Corticosteroid Hormone Receptor Agonists
Infectious Disease Approved 2020-08-10

CIPROFLOXACIN AND DEXAMETHASONE is indicated for the treatment of Acute Otitis Media; Acute Otitis Externa.

Source: FDA Label • UPSHER SMITH LABS • Corticosteroid

How CIPROFLOXACIN AND DEXAMETHASONE Works

Ciprofloxacin is a fluoroquinolone antibacterial that targets susceptible bacteria. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines. This results in decreased edema, fibrin deposition, capillary leakage, and reduced migration of inflammatory cells to the site of infection.

Source: FDA Label
5
Indications
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-08-10
Routes
OTIC
Dosage Forms
SUSPENSION/DROPS

CIPROFLOXACIN AND DEXAMETHASONE Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2020 to 2026
Jan 2026 ORIGINAL
Update
Jul 2025 SUPPL
Label · Labeling
Mar 2024 ORIGINAL
Update

What CIPROFLOXACIN AND DEXAMETHASONE Treats

2 indications

CIPROFLOXACIN AND DEXAMETHASONE is approved for 2 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acute Otitis Media
  • Acute Otitis Externa
Source: FDA Label

CIPROFLOXACIN AND DEXAMETHASONE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 6 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CIPROFLOXACIN AND DEXAMETHASONE

3 of 10

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AUGMENTIN ES-600
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
AZITHROMYCIN
AZITHROMYCIN
1 shared
Sun Pharma
Shared indications:
BACTRIM
SULFAMETHOXAZOLE
1 shared
Sun Pharma
Shared indications:
📋

Clinical Trial Registry

75 trials
Trial Sponsor ID Phase Status Title
NCT04791579 Pro00108452 Ph 2 recruiting Antibiotic Prophylaxis for Neurogenic Bladder Botox
NCT01243437 CDC-NCEZID-5859 Ph 2 completed A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
NCT04948463 ELSA-FN 74690 Ph 4 completed Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT05294588 21-0498 DMID 21-0018, U01AI162457-01 Ph 2 completed Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
NCT05274672 022-046 Ph 4 withdrawn Role of Prophylactic Postoperative Antibiotics in HoLEP
NCT03012360 TAVeM2 2015_66 2016-000735-41 Ph 4 terminated Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
NCT03850379 results posted 12124) Ph 2 completed Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
NCT05846399 CATBITE 2092043 Ph 4 recruiting CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
NCT04523987 PA02/07/18 Ph 1 active not recruiting A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
NCT05844735 PDY16917 U1111-1255-5054 Ph 1 completed A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
NCT04444440 Pro00101838 Ph 4 recruiting Antibiotic Prophylaxis for Bladder Botox
NCT07150065 107 Ph 2 completed Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever
NCT07016165 KE/FK/0517/EC/2025 Ph 4 recruiting Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07028424 PANORAMIX PANORAMIX G-116 PRODIGE 105 Ph 2 not yet recruiting PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
NCT01753115 results posted EBS.AVA.009 Ph 2 completed Ciprofloxacin BioThrax Co-Administration Study
NCT03692715 APPEAL CLUE Ph 4 completed Antibiotic Prophylaxis Before Shock Wave Lithotripsy
NCT04110340 IMASOY 45-18 Ph 3 completed Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
NCT03862170 BRP30 AA-HCLM-14-033 Ph 3 terminated Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
NCT06709196 REINFORCE 2024-514312-27-00 2024-514312-27-00 Ph 4 recruiting Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
NCT05462496 STUDY-21-01814 Ph 2 recruiting Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT02765256 Holiday results posted 823635 Ph 2 completed Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
NCT02598362 2014-004638-24 Ph 4 completed Pharmacokinetics of Ciprofloxacin in Pediatric Patients
NCT02620007 TEOREM P140503 Ph 2 terminated Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
NCT04147260 results posted 1407-0037 Ph 1 completed Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
NCT03854929 CIPAZ 26EN Ph 4 completed Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
NCT03262142 Target-ABC coptrin2 Ph 4 terminated Targeted AntiBiotics for Chronic Pulmonary Diseases
NCT03228108 pro-SWAP pro-SWAP104622 Ph 4 completed Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
NCT04698057 ACACIA ACACIA Ph 3 withdrawn Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.
NCT02790138 EARNEST results posted Vedolizumab-4004 U1111-1171-0918, 2015-003472-78 Ph 4 completed A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
NCT03476317 Holiday results posted 17-014343 5K23DK109136-02 Ph 2 completed Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
NCT04870138 results posted 09-0106 LptA Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
NCT03177720 ELF Cipro Ph 1 completed Evaluation of Innovative Tools in Development of Antibiotics
NCT00654108 07-0052 Ph 1 completed Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
NCT00832286 07-0053 Ph 1 completed Longitudinal Study of the Human Intestinal Microbiome
NCT03840811 results posted 09-0106 Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae
NCT02300220 results posted 14IC2031 2012-002198-72 Ph 3 completed Targeted Retreatment of COPD Exacerbations
NCT03354598 results posted IT001-301 Ph 3 completed Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
NCT03357614 results posted IT001-302 Ph 3 completed Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
NCT03358576 results posted IT001-303 Ph 3 completed Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
NCT00992329 HP-00043432 HHSF223200810030C Ph 1 completed Impact of Formulation on Ciprofloxacin Oral Absorption
NCT02816112 REaCT-TC2 OTT 16-03 Ph 4 completed Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
NCT01888822 MarPic63 Ph 4 terminated Antibiotic Prophylaxis in Laparoscopic Cholecystectomy
NCT01789203 results posted Pro00007510 IRB0612-0114 Ph 4 completed Ciprofloxacin for Prevention of BK Infection
NCT01783106 APRiCCOT Royal_Liverpool 2008-001137-99 Ph 2 completed Antibiotics and Hydroxychloroquine in Crohn's
NCT03366207 results posted IT004-401 Ph 4 completed Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
NCT03431675 Cipro chemoprophylaxis 2018 Ph 4 withdrawn Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
NCT02068846 results posted 12-0036 1R21DE023046-01A1 Ph 3 completed BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
NCT01659866 results posted STU00059558 EAM-237 Ph 4 completed Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01505634 results posted 7655-003 2011-005707-32, MK-7655-003 Ph 2 completed Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
NCT01952444 results posted AH110 Ph 1 completed Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Showing 50 of 75 trials

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CIPROFLOXACIN AND DEXAMETHASONE FDA Label Details

Indications & Usage

CIPROFLOXACIN AND DEXAMETHASONE is indicated for the treatment of Acute Otitis Media; Acute Otitis Externa.

Track CIPROFLOXACIN AND DEXAMETHASONE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.